About ProsTIC

ProsTIC is a world-leader in theranostics

Theranostic treatment for prostate cancer involves targeting prostate specific membrane antigen (PSMA) on prostate cancer cells – first with a radioactive molecule to reveal the cancer’s spread via a PET (Positron Emission Tomography) scan and then a similar radioactive molecule that kills cancer cells. ProsTIC have pioneered research globally, performing our first PSMA PET scan in 2014, and our first PSMA therapy in 2015. 

Prostate Theranostics and Imaging Centre of Excellence

Aims of the ProsTIC program 

The program has three aims.

1.  Accelerate clinical trial research 

Expanding the portfolio of clinical trials investigating the use of PSMA PET imaging and therapy targeting areas of high impact need not currently being addressed.  

2.  Education and Leadership 

Establishing a global hub of excellence to educate doctors, scientists, patients and the community about the application and benefits of this innovative technology.  

3.  Discovery research 

Furthering investigate next generation targets, develop biomarkers to predict and monitor response to PSMA therapy, optimise new combinations with PSMA therapy in pre-clinical models, explore the use of radio-guided surgery and artificial intelligence image interpretation. 

ProsTIC Contact 

Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

ProsTIC resources